HAE HAEMONETICS CORP
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 313143 · Fiscal year ends 04/03
Financial factors as of 2026-09-26 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY4.1%
TTM net income YoY-38.2%
TTM EPS YoY-33.9%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR-6.8%
Margins
Gross margin59.6%
Operating margin12.8%
Net margin7.5%
FCF margin21.6%
EBITDA margin20.7%
Returns
ROE11.9%
ROA4.3%
ROIC (approx.)7.3%
Asset turnover0.57x
Leverage & solvency
Liabilities / assets62.7%
Debt / equity1.25x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.32x
Accruals ratio-9.9%
Payout ratio—
Capex / revenue3.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2027Q22026-09-26 | 2027Q12026-06-27 | 2026Q4*2026-03-28 | 2026Q32025-12-27 | 2026Q22025-09-27 | 2026Q12025-06-28 | 2025Q4*2025-03-29 | 2025Q32024-12-28 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $357.76M | $339.38M | $346.35M | $338.97M | $327.31M | $321.39M | $330.60M | $348.54M |
| Cost of revenue | $136.85M | $136.58M | $148.14M | $136.58M | $132.57M | $129.15M | $137.55M | $155.00M |
| Gross profit | $220.91M | $202.80M | $198.21M | $202.39M | $194.74M | $192.24M | $193.05M | $193.55M |
| R&D expense | $17.03M | $16.20M | $14.45M | $14.19M | $14.87M | $16.26M | $15.91M | $15.83M |
| SG&A expense | $118.36M | $118.94M | $120.93M | $109.15M | $101.61M | $110.72M | $115.14M | $106.46M |
| Operating income | $75.12M | $57.46M | -$23.02M | $67.40M | $58.49M | $53.87M | $71.33M | $59.03M |
| Pretax income | $62.86M | $47.57M | -$28.40M | $59.98M | $51.28M | $45.17M | $70.74M | $49.92M |
| Income tax | $16.55M | $14.56M | -$8.25M | $15.23M | $12.60M | $11.14M | $12.76M | $12.42M |
| Net income | $46.30M | $33.01M | -$20.15M | $44.74M | $38.68M | $34.03M | $57.98M | $37.49M |
| EBITDA | $102.88M | $84.57M | $4.29M | $94.78M | $86.75M | $82.63M | $99.54M | $88.05M |
| EPS (basic) | 1.02 | 0.73 | — | 0.96 | 0.81 | 0.71 | — | 0.75 |
| EPS (diluted) | 1.00 | 0.72 | — | 0.95 | 0.81 | 0.70 | — | 0.74 |
| Weighted avg. shares (diluted) | 46.46M | 45.70M | — | 46.99M | 47.66M | 48.35M | — | 50.64M |
| Balance sheet | ||||||||
| Cash & equivalents | $260.71M | $223.38M | $245.44M | $363.37M | $296.43M | $292.90M | $306.76M | $320.85M |
| Receivables | $224.95M | $216.07M | $216.85M | $195.71M | $207.07M | $200.75M | $202.66M | $211.95M |
| Inventory | $305.01M | $306.74M | $306.37M | $321.19M | $336.21M | $360.53M | $365.14M | $359.61M |
| Current assets | $855.53M | $810.83M | $834.88M | $943.67M | $899.68M | $913.16M | $934.98M | $1.01B |
| PP&E, net | $307.92M | $303.78M | $305.76M | $297.23M | $292.48M | $286.87M | $284.05M | $286.11M |
| Goodwill | $657.10M | $656.88M | $656.37M | $606.83M | $606.10M | $607.30M | $604.27M | $605.27M |
| Intangibles | $426.36M | $434.51M | $447.65M | $419.73M | $428.36M | $450.63M | $455.74M | $465.62M |
| Total assets | $2.41B | $2.37B | $2.40B | $2.49B | $2.44B | $2.46B | $2.45B | $2.53B |
| Current liabilities | $300.84M | $263.24M | $282.60M | $539.87M | $548.32M | $531.41M | $578.11M | $253.23M |
| Short-term debt | $9.64M | $4.96M | $5.01M | $304.75M | $304.33M | $303.95M | $303.56M | $5.08M |
| Long-term debt | $1.11B | $1.17B | $1.22B | $919.99M | $920.39M | $920.83M | $921.23M | $1.22B |
| Total debt | $1.12B | $1.17B | $1.22B | $1.22B | $1.22B | $1.22B | $1.22B | $1.22B |
| Total liabilities | $1.51B | $1.53B | $1.60B | $1.58B | $1.59B | $1.58B | $1.63B | $1.62B |
| Shareholders' equity | $898.50M | $837.10M | $796.32M | $911.45M | $849.17M | $882.30M | $820.84M | $906.86M |
| Net debt | $863.05M | $950.77M | $979.14M | $861.37M | $928.30M | $931.88M | $918.02M | $903.99M |
| Shares outstanding | 45.52M | 45.47M | 45.25M | 46.83M | 46.75M | 48.16M | 48.22M | 50.24M |
| Cash flow statement | ||||||||
| Operating cash flow | $128.10M | $52.32M | $70.94M | $93.56M | $111.32M | $17.39M | $116.56M | $43.77M |
| Capital expenditure | $14.77M | $7.91M | $17.66M | $6.35M | $5.02M | $3.75M | $15.64M | $8.55M |
| Free cash flow | $113.33M | $44.42M | $53.28M | $87.22M | $106.31M | $13.64M | $100.91M | $35.22M |
| Investing cash flow | -$24.29M | -$22.23M | -$86.61M | -$29.47M | -$30.47M | -$33.00M | $18.04M | -$17.37M |
| Financing cash flow | -$67.61M | -$51.53M | -$101.50M | $2.03M | -$76.55M | -$2.44M | -$151.45M | $1.38M |
| Depreciation & amortization | $27.76M | $27.11M | $27.32M | $27.39M | $28.25M | $28.76M | $28.21M | $29.02M |
| Stock-based compensation | $10.23M | $9.31M | $9.13M | $7.80M | $7.59M | $9.31M | $6.94M | $8.21M |
| Share buybacks | — | — | $100.00M | $0 | — | — | $150.00M | $0 |
Free plan shows the latest 8 periods; Pro shows all 70 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.